TransMedics to Present at the Canaccord Genuity 42nd Annual Growth Conference
07/26/2022 - 04:05 PM
ANDOVER, Mass. July 26, 2022 nd Annual Growth Conference at the InterContinental Boston Hotel. Management is scheduled to present on Wednesday, August 10, 2022 , at 8:00 a.m. Eastern Standard Time .
Event: Canaccord Genuity 42nd Annual Growth Conference Date: Wednesday, August 10, 2022 8:00 a.m. ET
A live and archived webcast of the fireside chat will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/ .
About TransMedics Group, Inc. TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts , the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
Investor Contact: Brian Johnston transmedics.com
https://www.prnewswire.com/news-releases/transmedics-to-present-at-the-canaccord-genuity-42nd-annual-growth-conference-301593592.html
SOURCE TransMedics Group, Inc.
TMDX Rankings
#3404 Ranked by Stock Gains
TMDX Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Tags
Medical Specialties, Health Technology, Manufacturing, Surgical and Medical Instrument Manufacturing
Country
US
City
Andover
About TMDX
transmedics inc. is the world’s leader in portable ex-vivo perfusion and assessment of donor organs for transplantation. the company was founded to address the need for more and better organs for transplantation, and is focused on transforming the standard of care – increasing organ utilization, improving patient outcomes, and reducing transplant costs throughout the heath care system. the ocs™ lung and ocs™ heart systems are ce-marked and in commercial use outside the us, and are currently being reviewed by the fda for u.s. market access. the ocs™ liver is in an fda pivotal trial (the ocs™ liver protect trial) in the united states and a ce-mark trial in (the revive trial) in europe.
